Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT)...

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)

In a report released yesterday, Benjamin Burnett from Wells Fargo assigned a Buy rating to Keros Therapeutics, with a price target of $18.00. Burne...

Wells Fargo Issues a Buy Rating on Keros Therapeutics (KROS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Relay Therapeutics (RLAY) and Keros Therapeutics (KROS). Relay Th...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Relay Therapeutics (RLAY) and Keros Therapeutics (KROS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)

The latest update is out from Kross Limited ( ($IN:KROSS) ). Kross Limited has notified both BSE Limited and the National Stock Exchange of India t...

Kross Limited Publishes Unaudited Q1 FY27 Results in National Dailies

An update from Keros Therapeutics ( ($KROS) ) is now available. On July 17, 2026, Keros Therapeutics announced that Chief Financial Officer Keith R...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KROS	$11.15	+4.69%	319.63K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KROS	$11.15	+4.7%	319.63K
3
4
5
6

KROS

KROS

Get Keros Therapeutics, Inc. Data in Excel

Get Keros Therapeutics, Inc. Data in Excel